Horizon Pharma PLC (NASDAQ:HZNP) – Equities researchers at Cantor Fitzgerald increased their FY2018 earnings estimates for Horizon Pharma PLC in a note issued to investors on Tuesday. Cantor Fitzgerald analyst L. Chen now anticipates that the biopharmaceutical company will post earnings per share of $1.09 for the year, up from their prior estimate of $0.80. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price objective on the stock.

A number of other equities analysts have also recently commented on HZNP. Jefferies Group LLC set a $26.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Wednesday, April 12th. BMO Capital Markets reaffirmed a “buy” rating and set a $17.00 price target (down from $24.00) on shares of Horizon Pharma PLC in a research note on Tuesday, May 9th. Mizuho cut shares of Horizon Pharma PLC from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $22.00 to $10.00 in a research note on Tuesday, May 9th. Cowen and Company set a $20.00 price target on shares of Horizon Pharma PLC and gave the stock an “outperform” rating in a research note on Tuesday, May 9th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target (down from $35.00) on shares of Horizon Pharma PLC in a research note on Tuesday, May 9th. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Horizon Pharma PLC currently has an average rating of “Buy” and an average price target of $19.86.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Boost Earnings Estimates for Horizon Pharma PLC (HZNP)” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/cantor-fitzgerald-analysts-boost-earnings-estimates-for-horizon-pharma-plc-hznp.html.

Horizon Pharma PLC (NASDAQ:HZNP) traded down 4.27% during midday trading on Thursday, hitting $11.43. The company had a trading volume of 2,625,972 shares. The company’s 50 day moving average is $12.44 and its 200-day moving average is $13.70. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $23.44. The company’s market cap is $1.87 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.29. The business had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The business’s revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.56 EPS.

A number of large investors have recently added to or reduced their stakes in HZNP. BlackRock Inc. raised its stake in Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after buying an additional 13,241,875 shares in the last quarter. Vanguard Group Inc. raised its stake in Horizon Pharma PLC by 4.1% in the first quarter. Vanguard Group Inc. now owns 12,749,275 shares of the biopharmaceutical company’s stock valued at $188,434,000 after buying an additional 506,596 shares in the last quarter. Janus Capital Management LLC raised its stake in Horizon Pharma PLC by 19.4% in the first quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock valued at $65,173,000 after buying an additional 717,643 shares in the last quarter. State Street Corp raised its stake in Horizon Pharma PLC by 1.0% in the first quarter. State Street Corp now owns 4,382,120 shares of the biopharmaceutical company’s stock valued at $64,766,000 after buying an additional 42,142 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in Horizon Pharma PLC by 14.8% in the first quarter. Alliancebernstein L.P. now owns 4,064,995 shares of the biopharmaceutical company’s stock valued at $60,081,000 after buying an additional 525,486 shares in the last quarter. 82.95% of the stock is owned by institutional investors.

Horizon Pharma PLC announced that its board has approved a stock repurchase plan on Monday, May 8th that allows the company to repurchase 1,000% of shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Earnings History and Estimates for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.